摘要
本研究旨在探讨急性布鲁菌病患者治疗前后的肠道菌群特征,揭示肠道微生物群落与布鲁菌病发生发展的潜在关联。本研究收集了16名急性未治和3名治疗后布鲁菌病患者的粪便样本,进行16S rRNA高通量测序,并在NCBI公共数据库上匹配40名中国健康对照的测序数据进行分析。与健康对照组相比,布鲁菌病患者的肠道微生物群落丰富度和多样性均较低(P<0.05)。差异物种分析表明,布鲁菌病组中放线菌门(Actinobacteria)及其下属的双歧杆菌科(Bifidobacteriaceae)和柯林斯菌属(Collinsella)的丰度较高。抗菌药物治疗进一步降低了布鲁菌病患者的肠道微生物多样性,并富集了革兰氏阳性菌如肠球菌属(Enterococcus)、棒状杆菌科(Corynebacteriaceae)和乳酸菌目(Lactobacillales)。采用微生物群落功能预测工具(phylogenetic investigation of communities by reconstruction of unobserved states 2,PICRUSt2)分析发现,急性未治疗、治疗后和健康对照3个组中18个KEGG通路存在显著差异(P<0.05),其中布鲁菌病组中76.9%(10/13)的代谢通路增加,提示布鲁菌感染后代谢活动增强。本研究表明,布鲁菌病患者肠道微生物多样性降低,而与疾病进展相关的放线菌门(Actinobacteria)过度生长,这为布鲁菌病的发病机制提供了新的视角。
Little was known regarding the differences in the gut microbiomes of brucellosis patients and healthy subjects(HCs).To explore the characteristics of the gut microbiota in brucellosis patients,16S rRNA sequencing data from 40 Chinese HCs,16 acute and 3 post-treatment brucellosis were analyzed.Acute and post-treatment brucellosis were lower in community richness and microbial diversity compared to HCs(P<0.05).Actinobacteria and subordinate genera,Bifidobacteriaceae and Coriobacteriaceae,were higher in acute brucellosis group.Antibiotic treatment further reduced microbial diversity and enriched Gram-positive bacteria such as Enterococcus,Corynebacteriaceae and Lactobacillales.PICRUSt2(phylogenetic investigation of communities by reconstruction of unobserved states 2)analysis identified significant differences in 18 KEGG pathways,among which 76.9%(10/13)metabolism pathway increased in brucellosis group compared to HCs,which indicated that the metabolic activity was enhanced after Brucella infection.In conclusion,this cohort study has detected altered microbiota and decreased microbial diversity in the brucellosis patients,marked by a significant overgrowth of disease-related microbes from Actinobacteria,which is a new perspective for the pathogenesis of brucellosis.
作者
袁关敏
王红羽
李丹
王妍
郭薇
王岩
薛荃璘
姜宁
仇超
周旸
刘洪艳
艾静文
张文宏
YUAN Guanmin;WANG Hongyu;LI Dan;WANG Yan;GUO Wei;WANG Yan;XUE Quanlin;JIANG Ning;QIU Chao;ZHOU Yang;LIU Hongyan;AI Jingwen;ZHANG Wenhong(Department of Infectious Diseases,Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response,National Medical Center for Infectious Diseases,Huashan Hospital,Shanghai Medical College,Fudan University,Shanghai 200040,China;Department of Science and Education,The Sixt People’s Hospital of Shenyang,Emergency Treatment and Innovation Center of Public Health Emergencies,Shenyang 110006,Liaoning Province,China;Department of Infectious Diseases,The Sixth People’s Hospital of Shenyang,Emergency Treatment and Innovation Center of Public Health Emergencies,Shenyang Brucellosis Clinical Research Center,Shenyang 110006,Liaoning Province,China;Shanghai Sci-Tech Inno Center for Infection&Immunity,Shanghai 200052,China)
出处
《微生物与感染》
2025年第2期86-96,共11页
Journal of Microbes and Infections
基金
上海市卫健委(GWV-10.1-XK1)
上海感染与免疫科技创新中心(SSH-202405)
国家重点研发计划(2022YFC2009802)
上海市重大专项(HS2021SHZX001)
上海市科委(20dz2260100,21NL2600100,20Z11901100)
辽宁省2021年民生科技计划(2021JH2/10300056)
沈阳市卫生健康委科研课题(2020035,2021045)。
